|Quick Links

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549
FORM 10-QSB

(Mark One)

[ x ]     QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2001
OR

[    ]       TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE ACT

For the transition period from
 to
Commission File Number 1-11055

Epigen, Inc.(Exact name of small business issuer as specified in its charter)

Delaware(State or other jurisdiction of incorporation or organization)

04-3120172(I.R.S. Employer Identification No.)

69 North Tower Hill Road, PO Box L, Millbrook, NY 12545(Address of principal executive offices) (Zip Code)

(845) 677-5317(Issuer's telephone number, including area code)

n/a(Former name, former address and former fiscal year, if changed since last report)

Check whether the issuer (1) has filed all reports required to be filed by Section 13 or 15(d) of the
Exchange Act during the past 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days.   YES [ x ]   NO [   ]

The number of shares outstanding of the issuers Common Stock, par value $.001 per share, at
November 9, 2001 was 1,394,250.

Transitional Small Business Disclosure Format (check one):  
YES [ x ]   NO [   ]
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

|EPIGEN, INC.
                         (Formerly COD Associates, L.P.)
                          (A Development Stage Company)

                                      INDEX


                                                                           Page
                                                                          Number
                                                                          ------
PART I    FINANCIAL INFORMATION

Item 1.   Financial Statements
          Balance Sheets
             at September 30, 2001 and December 31, 2000 ..............      1

          Statements of Operations
             for the nine month periods ended September 30, 2001
             and September 30, 2000, and for the three month periods
             ended September 30, 2001 and September 30, 2000, and
             cumulative from inception (January 28, 1987) to
             September 30, 2001 .......................................      2

          Statements of Cash Flows
             for the nine month periods ended September 30, 2001
             and September 30, 2000, and cumulative from
             inception (January 28, 1987) to September 30, 2001 .......      3

          Notes to Financial Statements ...............................  4 - 6

Item 2.   Management's Discussion and Analysis or Plan of Operation ...  7 - 9

PART II   OTHER INFORMATION

Item 2(c) Information Regarding the Sale of Unregistered Securities
          During the Three Month Period Ended September 30, 2001 ......     10

Item 5.   Other Information ...........................................     10

Item 6.   Exhibits and Reports on Form 8-K ............................     11


SIGNATURES ............................................................     12
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

|PART I     FINANCIAL INFORMATION

Item 1.  Financial Statements

EPIGEN, INC.
                               (Formerly COD Associates, L.P.)
                                (A Development Stage Company)
                                        BALANCE SHEETS

                                                               September 30,    December 31,
                                                                   2001            2000
                                                               -------------   -------------
ASSETS
Current Assets:
   Cash and cash equivalents ...............................   $    222,501    $     59,199
   Loan and interest receivable ............................        107,869         164,165
                                                               -------------   -------------
      Total Current Assets .................................        330,370         223,364

Office and lab equipment, net of accumulated depreciation of
   $59,152 and $55,276 .....................................         20,407          14,862
                                                               -------------   -------------
      Total Assets .........................................   $    350,777    $    238,226
                                                               =============   =============

LIABILITIES & STOCKHOLDERS' EQUITY
Current Liabilities:
   Note payable demand .....................................   $    105,805    $    105,805
   Notes payable - Officer .................................        304,142         361,214
   Notes payable - Other ...................................        550,000            --
   Accrued interest - notes payable ........................        118,517          97,019
   Accrued direct research & development costs .............        615,225         570,252
   Accrued professional fees ...............................        507,524         359,858
   Accrued payroll .........................................        357,983         291,182
   Other accrued expenses ..................................        132,062         199,997
                                                               -------------   -------------
      Total Current Liabilities ............................      2,691,258       1,985,327
                                                               -------------   -------------

Long-term Liabilities:
   Notes payable - Other, net of current portion ...........         31,337            --
                                                               -------------   -------------
      Total Long-term Liabilities ..........................         31,337            --
                                                               -------------   -------------

STOCKHOLDERS' EQUITY
   Preferred Stock - 15,000,000 shares authorized of which:
     3,000,000 shares designated as Series A, $.001 par
       value, issued and outstanding - 1,843,306 shares at
       September 30, 2001 ..................................          1,843           1,843
     500,000 shares designated as Series B, $.001 par
       value, issued and outstanding - 375,000 shares at
       September 30, 2001 ..................................            375             375
   Common Stock - 50,000,000 shares authorized,
     $.001 par value, issued and outstanding - 13,935,972
       shares at September 30, 2001 ........................         13,936          12,567
   Additional paid-in capital ..............................     20,996,954      19,999,152
   Deficit accumulated during development stage ............    (23,384,926)    (21,761,038)
                                                               -------------   -------------
      Total Stockholders' Equity ...........................     (2,371,818)     (1,747,101)
                                                               -------------   -------------
      Total Liabilities & Stockholders' Equity .............   $    350,777    $    238,226
                                                               =============   =============

          The accompanying notes are an integral part of these financial statements.

                                             -1-
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

|EPIGEN, INC.
                                                   (Formerly COD Associates, L.P.)
                                                    (A Development Stage Company)
                                                      STATEMENTS OF OPERATIONS

                                                                                                                       Cumulative
                                                      For the Three   For the Three   For the Nine    For the Nine       from
                                                      Months Ended    Months Ended    Months Ended    Months Ended    Inception to
                                                      September 30,   September 30,   September 30,   September 30,   September 30,
                                                          2001            2000            2001            2000            2001
                                                      -------------   -------------   -------------   -------------   -------------
Revenues:
 Contract research ................................   $       --      $       --      $       --      $       --      $      5,000
 Licensing fees ...................................           --              --              --              --             1,600
 Management fee income ............................           --              --              --              --            23,219
 Interest income ..................................          2,337           3,534           8,924          29,164         261,333
                                                      -------------   -------------   -------------   -------------   -------------
                                                             2,337           3,534           8,924          29,164         291,152
                                                      -------------   -------------   -------------   -------------   -------------
Operating Costs & Expenses:
 Direct research & development ....................        164,663         330,910         454,919         667,343       9,225,257
 General & administrative .........................        499,097         245,248       1,135,622         742,423      12,479,928
 Fees due to General Partner of the Predecessor
  & affiliates, forgiven and contributed to capital           --              --              --              --         1,188,893
 Interest expense, net ............................         16,132          17,228          42,272         123,711         990,594
                                                      -------------   -------------   -------------   -------------   -------------
      Total Operating Costs & Expenses ............        679,892         593,386       1,632,813       1,533,477      23,884,672
                                                      -------------   -------------   -------------   -------------   -------------

Net (loss) before extraordinary items .............       (677,555)       (589,852)     (1,623,889)     (1,504,313)    (23,593,520)

Extraordinary Item:
 Cancellation of debt income ......................           --           154,109            --           154,109         208,594
                                                      -------------   -------------   -------------   -------------   -------------

Net (loss) ........................................   $   (677,555)   $   (435,743)   $ (1,623,889)   $ (1,350,204)   $(23,384,926)
                                                      =============   =============   =============   =============   =============

Net (loss) per common share .......................   $      (0.05)   $      (0.04)   $      (0.12)   $      (0.17)
                                                      =============   =============   =============   =============

Weighted average number
 of shares of Common Stock outstanding ............     13,926,711      10,621,082      13,375,333       7,749,516
                                                      =============   =============   =============   =============

                             The accompanying notes are an integral part of these financial statements.

                                                                 -2-
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

|EPIGEN, INC.
                                     (Formerly COD Associates, L.P.)
                                      (A Development Stage Company)
                                         STATEMENTS OF CASH FLOWS

                                                                                            Cumulative
                                                           For the Nine    For the Nine        from
                                                           Months Ended    Months Ended    Inception to
                                                           September 30,   September 30,   September 30,
                                                               2001            2000            2001
                                                           -------------   -------------   -------------
Cash Flows From Operating Activities:
 Net loss ..............................................   $ (1,623,889)   $ (1,350,204)   $(23,384,926)
 Adjustments to reconcile net loss to
  net cash from operating activities:
   Depreciation and amortization expense ...............          3,876           4,502         120,097
   Non-cash expenses paid in equity interest ...........           --               (36)      2,811,376
   Non-cash compensation expense associated
    with the grant of stock options and warrants .......           --              --           427,964
 Debt converted to equity ..............................         77,120       2,812,306       3,910,257
 Changes in operating assets and liabilities:
  Increase (decrease) in accrued direct
   research and development costs ......................         44,973        (103,448)        615,225
  Increase (decrease) in accrued professional fees .....        147,666           5,100         507,524
  Increase (decrease) in accrued payroll ...............         66,801      (1,153,828)        357,983
  Increase (decrease) in accrued expenses to
   affiliates, printing charges and other expenses .....        (46,437)        (48,206)        250,579
                                                           -------------   -------------   -------------
     Net Cash Provided By (Used In) Operating Activities     (1,329,890)        166,186     (14,383,921)
                                                           -------------   -------------   -------------

Cash Flows From Investing Activities:
 Purchase of office and lab equipment ..................         (9,420)           --           (83,554)
 Retirement of treasury stock ..........................           --               347            --
 Decrease (increase) in note and interest receivable
  from an officer/shareholder ..........................         56,296        (160,631)       (107,869)
 Decrease (increase) in other assets ...................           --              --            (3,025)
 Increase in organizational costs ......................           --              --           (53,925)
                                                           -------------   -------------   -------------
     Net Cash Provided By (Used In) Investing Activities         46,876        (160,284)       (248,373)
                                                           -------------   -------------   -------------

Cash Flows from Financing Activities:
 Proceeds from issuance of Common Stock ................        922,051         278,460      10,901,911
 Increase (decrease) in note payable - Officer .........        (57,072)           --           304,142
 Capital contributions .................................           --              --         2,141,600
 Proceeds from issuance of Preferred Stock .............           --           375,000         820,000
 Increase (decrease) in note payable-demand ............           --           (15,000)        105,805
 Net increase (decrease) in notes payable - other ......        581,337      (1,125,000)        581,337
                                                           -------------   -------------   -------------
     Net Cash Provided By (Used In) Financing Activities      1,446,316        (486,540)     14,854,795
                                                           -------------   -------------   -------------

Net increase (decrease) in cash and cash equivalents ...        163,302        (480,638)        222,501
Cash and cash equivalents, beginning of period .........         59,199         521,766            --
                                                           -------------   -------------   -------------

Cash and cash equivalents, end of period ...............   $    222,501    $     41,128    $    222,501
                                                           =============   =============   ==============

                The accompanying notes are an integral part of these financial statements.

                                                   -3-
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

|EPIGEN, INC.
(Formerly COD Associates, L.P.)
(A Development Stage Company)
NOTES TO FINANCIAL STATEMENTS1.  Basis of Presentation

The financial statements as of September 30, 2001 are unaudited, but include all
adjustments  (consisting  of normal,  recurring  adjustments)  which the Company
considers   necessary  for  a  fair   presentation  of  such  interim  financial
statements. The results of operations for the nine month periods ended September
30, 2001 and September 30, 2000, and the three month periods ended September 30,
2001 and  September 30, 2000 are not  necessarily  indicative of the results for
the entire year.  The financial  statements and notes are presented as permitted
by Form 10-QSB and do not contain certain information  included in the Company's
annual financial statements and notes.

2.  Cash and Cash Equivalents

Cash and cash  equivalents  include all funds held in checking  and money market
bank accounts.

3.  Net Loss per Share

Net loss per share is based on the weighted  average  number of shares of Common
Stock outstanding during the period.  All outstanding  warrants and options have
been excluded from the calculation as they are antidilutive.

4.  Licensing Agreements

The Company's technology was originally licensed from Boston Biomedical Research
Institute  ("BBRI").  In  1993,  BBRI  transferred  ownership  of  all  licensed
technology  to Epigen,  Inc.  Conditions  in the transfer of ownership  provide,
among other things, for royalty payments to BBRI. Currently, royalty payments to
BBRI are capped at 3% of the net  selling  price of  products  containing  Human
Carcinoma Antigen or epiglycanin.

During 1992,  the Company  entered into a contract  with the  University of Oslo
("Oslo University") in close collaboration with BBRI for the characterization of
the Human Carcinoma Antigen.  The agreement calls for payment to Oslo University
of 1% of net sales for any human  therapeutic  product utilizing these patent or
biological material rights sold to third parties.

During 1993, the Company  entered into an agreement with  Massachusetts  General
Hospital  ("MGH")  to  license  certain  antibodies  for use in  developing  the
in-vitro diagnostic test, the in-vivo imaging agent and the therapeutic vaccine.
Under the agreement, the Company is required to pay royalties ranging from 2% to
5% of the net sales  price,  as defined,  depending  on the country in which the
product is sold.  The term of the  agreement  expires,  on a  country-by-country
basis,  eight years after the first  commercial  sale or for the life of a valid
patent in a country, whichever occurs first.
-4-
EPIGEN, INC.
(Formerly COD Associates, L.P.)
(A Development Stage Company)
NOTES TO FINANCIAL STATEMENTS4.  Licensing Agreements (continued)

Pursuant to the  Company's  agreement  with BBRI, if royalties are to be paid to
both  BBRI and MGH,  the  aggregate  royalty  payable  to BBRI and MGH shall not
exceed 6% of the net proceeds to the Company from sales of any licensed  product
or process. On June 12, 1995, MGH agreed to reduce royalty payments due pursuant
to the June 1, 1993 agreement by 50% to between 1% and 2.5%.

The Company  entered into an  agreement  dated as of March 31, 1999 with Vacold,
LLC for the  creation  of an IgG  antibody.  In lieu of  cash,  Vacold  received
433,705 shares of the Company's Common Stock. In addition,  Vacold is to receive
a 3% royalty on Epigen's  sales that  include any IgG  antibodies  developed  in
Vacold's  laboratory.  A second  contract was negotiated with Vacold for ongoing
R&D. Vacold was to be responsible for the optimization and  demonstration of the
new assay to prospective  strategic  partners.  The Agreements  with Vacold were
terminated on September 28, 2000 by mutual consent.

In February  2001,  the Company  opened a new  laboratory  at the  University of
Rochester (the "University") in Rochester,  New York to continue the development
of its diagnostics and therapeutics.  Under the terms of the License  Agreement,
the  rent  to be  paid  to the  University  will  be  $3,333.00  per  month.  In
conjunction with this Agreement,  there is a Restricted Stock Agreement with the
Research  Foundation of the University of Rochester (the  "Foundation")  for the
period February 1, 2001 to January 31, 2002 whereby the Foundation is to receive
26,087  shares of Common Stock of the Company.  The shares of stock shall accrue
to the Foundation one twelfth of the stipulated  amount on a monthly basis.  For
the period  February 1, 2001 to July 31, 2001,  the Foundation  received  13,044
shares of Common Stock. 4,348 shares have accrued, covering the period August 1,
2001 to September 30, 2001.

5.  Loan and Interest Receivable

On June 7, 2000,  Donald C.  Fresne,  Chairman of the Board and Chief  Executive
Officer of the Company,  issued a Promissory Note to Epigen,  Inc. in the amount
of $156,214 at an annual  interest  rate of 9%. The terms of the Note state that
three annual equal  amounts of the principal  together with interest  accrued on
the  outstanding  amount  shall be paid in  coordination  with a note payable to
Donald C. Fresne,  (see Note 6) commencing on June 1, 2001. The total obligation
on June 1 was $66,609.65.
-5-
EPIGEN, INC.
(Formerly COD Associates, L.P.)
(A Development Stage Company)
NOTES TO FINANCIAL STATEMENTS6.  Loan and Interest Payable

Included in Notes  payable - Officer,  is a  Promissory  Note dated June 7, 2000
issued by Epigen,  Inc.  to Donald C.  Fresne,  Chairman  of the Board and Chief
Executive  Officer  of the  Company,  in the  amount  of  $356,214  at an annual
interest  rate of 9%. The terms of the note state that  $156,214  of this amount
shall  be paid  back  together  with  interest  thereon  in three  equal  annual
installments  commencing  on June 1, 2001.  The total  obligation  on June 1 was
$66,609.65. This was coordinated with a loan and interest receivable from Donald
Fresne (see Note 5).

7.  Equity Transactions During the Three Months Ended September 30, 2001

The Company  recorded the issuance of 24,000 shares of Common Stock at $1.00 per
share  to two  of the  Directors  of  the  Company  at  12,000  shares  each  in
satisfaction of the Company's obligation of Director fees due. These shares were
recorded at par value, with the balance of the price recorded as additional paid
in capital.

The Company  issued an additional  6,522 shares of Common Stock in  coordination
with a licensing  agreement as  enumerated  in Note 4. The value of these shares
for purposes of the licensing  agreement is $1.15 per share totaling $7,500. The
shares were issued at par with the balance of the price  recorded as  additional
paid in capital.

In August 2001, Lionel  Goldfrank,  III exercised Series I Warrants by investing
$300,000.  The  number of shares  which Mr.  Goldfrank  is to  receive  for such
exercise will be determined  based upon the closing price of securities  sold in
the Company's  anticipated  private placement of up to $7,000,000.  To date, the
number of shares has not been determined.  Therefore, the $300,000 received from
Mr.  Goldfrank has been recorded in Current Notes Payable - Other in the balance
sheet of these financial  statements.  In the event such private  placement does
not close, the exercise price per share of such Warrants will be $.56.
-6-


EPIGEN, INC.
(Formerly COD Associates, L.P.)
(A Development Stage Company)
Item 2.  Management's Discussion and Analysis or Plan of Operation

The Company  presently is  insolvent  and unable to pay its debts as they become
due.  Certain of the  officers  have agreed  temporarily  to allow part of their
salaries and other  benefits to accrue.  Currently,  liabilities  exceed assets.
Should a sufficient  number of the Company's  creditors  pursue the  obligations
owed  them,  the  Company  might  be  forced  into a  voluntary  or  involuntary
bankruptcy proceeding.

During the period  from June 28,  2000  through  August 2,  2000,  however,  the
Company  completed  a series of  conversions  of debt to stock,  primarily  with
existing stockholders and the Company's officers,  which reduced its outstanding
liabilities by an aggregate of $2,966,415  from  $4,607,906 to $1,641,491.  As a
result of such conversions,  the Company issued an aggregate of 2,393,114 shares
of its Common Stock,  and 1,493,306  shares of its Series A Preferred Stock. The
Company is  continuing  its  efforts to reduce its  liabilities  through  equity
conversions as appropriate opportunities are presented.

In addition to debt  reduction,  the Company  continues to pursue funding from a
variety of sources.  Effective July 12, 2001, the Company  entered into a letter
of  intent  for the  private  placement  of up to  $7,000,000  of the  Company's
securities.  However, there can be no assurance that such private placement will
be successful or that the Company will be successful in its efforts otherwise to
raise additional  capital.  The Company continues to pursue its business plan to
the extent resources permit.

The Company  believes that it has produced  enough data  indicating that the HCA
Test can be used as a confirmatory test for prostate cancer.

The Company does not presently  have the  resources to complete the  development
of, or conduct prospective  clinical trials on, new products.  It has never been
part of the  Company's  strategy to market any of its  products.  The Company is
focusing on the optimum financial  opportunity this technology should afford and
is presently  negotiating  a license  agreement  with a major  biopharmaceutical
company to distribute  the products upon FDA approval.  No assurance can be made
that  the  Company  will be  successful  in  negotiating  a  definitive  license
agreement  or  that,  upon  execution,  the  Company  will be  able to  complete
development  of the HCA Test in order to receive FDA approval or to commence its
manufacture and distribution.

Upon funding,  the Company  intends to complete the  development  of and conduct
prospective  clinical trials on its  confirmatory  test for prostate  cancer,  a
prerequisite for seeking FDA approval.

The Company has hired Paul Schnipelsky, Ph.D., former Vice President of Research
from  Ortho-Clinical  Diagnostics,  John L. Daiss, Ph.D., former Fellow, John C.
Mauck,  Ph.D.,  and several  technicians  formerly  employed  by  Ortho-Clinical
Diagnostics,  Inc.  The Company  also has  retained  Terry  Platt,  Ph.D.,  as a
consultant.  The Company  opened a laboratory at the  University of Rochester in
Rochester, New York in February 2001 where such persons continue the development
of the Company's products.
-7-
EPIGEN, INC.
(Formerly COD Associates, L.P.)
(A Development Stage Company)
Item 2.  Management's Discussion and Analysis or Plan of Operation (continued)

The Company,  through collaborations with hospitals in the Northeast and a major
biopharmaceutical  company,  has  completed a large  clinical  study on over 400
prostate cancer patients.  The Company believes that the results demonstrate the
viability of the HCA Test as a diagnostic  aid. The study  reveals the following
results in a comparison between its HCA and PSA:
Parameter            HCA             PSA
            -----------     ----------------     ------
            Sensitivity     96.4% (94%, 99%)      81.5%
            Specificity     92.2% (89%, 96%)      51.6%
            PPV(1)          90.9% (87%, 95%)      57.5%
            NPV(2)          97%   (95%, 99%)      77.6%

     (1) Positive Predictive Value
     (2) Negative Predictive Value

The above table was developed in  collaboration  with a major  biopharmaceutical
company.

Sensitivity  is a measure of true positive or false  negative.  If there are 100
lesions and a test identifies 80 of these,  the sensitivity is 80%. True (+) 80,
false negative (20).

Specificity  is a measure of true negative or false  positive.  If there are 100
patients with no lesions and a test  identifies 20 lesions,  the  specificity is
80%. True (-) 80, false (+) 20.

The  study  was  conducted  using  IgM  antibodies.  The  industry  prefers  IgG
antibodies because of their smaller size and faster reactivity.  The Company has
successfully  raised IgG antibodies  that are 20% of the size of IgM antibodies.
These  antibodies  have faster  reactivity and avoid problems  indigenous to IgM
antibodies.  The  Company is now  optimizing  its assay by testing  the  various
combinations of IgG and IgM antibodies to determine which  combination gives the
best results.

The Company has also entered  into  collaborations  with  hospitals to develop a
confirmatory  test for breast  cancer.  One of the  collaborators  has collected
serum samples from 500 patients who have had positive  mammograms and subsequent
biopsies. This will allow the Company to demonstrate the ability of the HCA Test
to  differentiate  between  cancer and normals  and  confirm  the  presence of a
carcinoma.  It is generally  accepted that  mammograms have a 95% false positive
rate.  The Company  believes  that the HCA Test should drop this false  positive
rate to 5 - 10%. The Company  believes from in-house  preliminary  data that the
HCA Test should also be an effective  confirmatory  test for breast  cancer.  As
soon as these data are  available,  a  presentation  will be made to prospective
strategic partners with the intent to license the technology. If successful, the
Company  believes  that the HCA Test  will  eliminate  the need for  unnecessary
sonograms and biopsies,  reduce  stress  experienced  by patients who have false
positives, and result in substantial savings to the health care industry.
-8-
EPIGEN, INC.
(Formerly COD Associates, L.P.)
(A Development Stage Company)
Item 2.  Management's Discussion and Analysis or Plan of Operation (continued)

In October 2000, the Company entered into a Memorandum of Understanding  ("MOU")
with Medarex, Inc., a biopharmaceutical company, to jointly develop and market a
human monoclonal antibody therapeutic  utilizing the Company's patented antigen.
A definitive agreement was signed effective August 10, 2001.

Preliminary in-vitro testing regarding the Company's  therapeutic has shown that
the vaccine  kills cancer  cells  within an hour  without harm to normal  cells.
Research on the  Company's  vaccine at Columbia  Presbyterian  has been deferred
until funding is available.

On June 6, 2001,  the Company signed an MOU with AltaRex Corp. The MOU calls for
the  Company  to  create  a  joint  collaboration  with  AltaRex  to  develop  a
therapeutic for epithelial  cancers that will  incorporate  Epigen's  monoclonal
antibodies and the HCA antigen in AltaRex's unique and proprietary  immunization
strategy.  AltaRex's technology combines the elevated levels of tumor-associated
antigens  frequently observed in the blood of cancer patients with low levels of
non-human  antibodies to form highly  immunogenic  circulating  immune complexes
that can induce the  patient's  own potent  immune  response  against the tumor.
Specifically,  combinations  of  Epigen's  anti-HCA  antibodies  and HCA will be
evaluated for  immunogenic  potential in AltaRex's  Dendritic Cell Assay System.
Potent immunogenic  combinations will be selected for further  investigation and
rapid development for Phase I clinical trials.
-9-


EPIGEN, INC.
(Formerly COD Associates, L.P.)
(A Development Stage Company)
PART II     OTHER INFORMATION



Item 2(c)  Information Regarding the Sale of Unregistered Securities During the Three Month Period Ended
September 30, 2001

In July 2001,  Registrant  issued to each of L. Courtney Schroder and Richard E.
Kent 12,000  shares of the Company's  Common Stock in lieu of  directors'  fees.
Registrant valued such shares at $1.00 per share.

In August 2001, Registrant issued to an affiliate of the University of Rochester
6,522 shares of the  Registrant's  Common Stock in lieu of a portion of the rent
owed by  Registrant  to the  University of Rochester for the lease of laboratory
space.  The  issuance  of such  shares in lieu of cash is  required  pursuant to
Registrant's  lease for such space.  Registrant  valued such shares at $1.15 per
share.

In addition,  in August 2001, Lionel Goldfrank,  III exercised Series I Warrants
by investing  $300,000.  The number of shares which Mr.  Goldfrank is to receive
for such exercise will be determined  based upon the closing price of securities
sold in the Company's anticipated private placement of up to $7,000,000.  In the
event such private  placement  does not close,  the exercise  price per share of
such Warrants will be $.56.

In  September  2001,  the  Company  issued  Promissory  Notes  in the  aggregate
principal  amount of $250,000 to two investors,  including Mr.  Goldfrank.  Such
Notes also had detachable warrants to purchase an aggregate of 111,607 shares of
the Company's  Common Stock at an exercise price of $1.16 per share,  subject to
adjustment in the event such private placement closes. In addition, in the event
such private  placement  closes  prior to December 31, 2001,  such Notes will be
automatically  converted into shares of the Company's equity  securities  issued
pursuant to such private  placement at a price per share of 90% of the price per
share paid by investors in such private placement.  If not previously converted,
on December 31, 2001 such Notes  automatically  will be converted into shares of
the Company's Common Stock at the rate of $.56 per share.



Item 5.  Other Information

Pursuant to a written  consent dated as of October 9, 2001,  the holders of
shares of  Registrant's  capital stock holding a majority of the votes of shares
on matters which may come before  Registrant's  shareholders for a vote approved
(i) a 1-for-10  reverse stock split of all classes of  Registrant's  outstanding
shares  of  capital  stock,  (ii)  amended  the terms of  Registrant's  Series B
Preferred  Stock to  extend  the  mandatory  redemption  date for such  Series B
Preferred  Stock from August 31, 2001 to March 31, 2002,  and (iii)  amended the
provisions   in   Registrant's   Certificate   of   Incorporation   relating  to
indemnification of Registrant's officers and directors and certain other persons
to bring such  provisions  into  conformity  with  current  laws of the State of
Delaware.  All such actions were  accomplished  through the filing of an Amended
and Restated Certificate of Incorporation of Registrant filed with the Secretary
of State of Delaware on November 8, 2001.  A copy of such  Amended and  Restated
Certificate of Incorporation,  as filed with the Secretary of State of Delaware,
is attached hereto as Exhibit 3.16.

-10-
EPIGEN, INC.
(Formerly COD Associates, L.P.)
(A Development Stage Company)


Item 6.  Exhibits and Reports on Form 8-K

Exhibits3.16 Amended and Restated Certificate of Incorporation as filed with the Secretary
of State of Delaware on November 8, 2001.Reports on Form 8-KThe Company  did not file any reports on Form 8-K during the three month  period
ended September 30, 2001.-11-
EPIGEN, INC.
(Formerly COD Associates, L.P.)
(A Development Stage Company)
SIGNATURES

In accordance with the requirements of the Securities Exchange Act of 1934, the Registrant caused this report to be signed on its
behalf by the undersigned thereunto duly authorized.

Dated:  November 9, 2001
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

| |  | EPIGEN, INC.
| |  | ------------
| |  | By:         

| |  | EPIGEN, INC.
| |  | ------------
| |  | By:         

|-12-
Quick Links
PART IFINANCIAL INFORMATION

   Item 1.  Financial Statements

        Balance Sheets
        Statements of Operations
        Statements of Cash Flows
        Notes to Financial Statements

   Item 2.  Management's Discussion and Analysis of Financial Condition and Results of OperationsPART IIOTHER INFORMATION
   Item 2(c) Information Regarding the Sale of Unregistered Securities During the Six Month Period Ended September 30, 2001
   Item 5 Other Information
   Item 6.  Exhibits and Reports on Form 8-K
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------